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DVT and the incidence of post-thrombotic sequelae
after long-term anticoagulation therapy have been
widely debated. Barritt and Jordan1 first demonstrat-
ed the benefits of anticoagulation in patients with
pulmonary embolism. It is generally accepted that
patients with a diagnosis of acute DVT must receive
systemic heparin followed by an oral anticoagulant;
however, controversy exists regarding the duration of
anticoagulation therapy. When considering the dura-
tion of anticoagulation therapy, the physician must
balance the risk of recurrence versus the risk of hem-
orrhagic complications. Several studies have tried to
stratify patients into groups that should receive short-
term anticoagulation (3 to 8 weeks) versus long-term
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Purpose: The long-term risk for recurrent deep venous thrombosis (DVT) and the incidence
of post-thrombotic syndrome (PTS) after long-term anticoagulation (LTA) therapy have
been widely debated. In this study, we compare the results of short-term anticoagulation
therapy versus conventional LTA therapy in patients with DVT of the lower extremity.
Methods: Baseline assessments of DVT symptoms and risk factors were recorded in 105
patients. Diagnosis was made using duplex ultrasound/venography. Patients were
sequentially assigned to 1 of the following treatment protocols: (A) conventional LTA
therapy, which included initial intravenous standard heparin followed by warfarin on
days 3 to 5 and was continued for 3 months for patients without pulmonary embolism
(PE); or (B) short-term therapy, which included the same heparin therapy followed by
warfarin on days 2 to 3 and was continued for 6 weeks only. Clinical and duplex ultra-
sound follow-up was done at 6 weeks, 3 and 6 months, and every 6 months thereafter.
Results: Risk factors, location of DVT, and mean age of the 2 groups were comparable.
Mean follow-up was 59 months. There were 4 immediate major complications in
patients of group A (4 of 54 [7%]; 2 PEs and 2 significant bleeds) and 3 in patients of
group B (3 of 51 [6%]; 1 PE and 2 bleeds). On long-term follow-up, 18 of 43 (42%)
patients in group A and 20 of 44 (46%) patients in group B had PTS. Similarly, 10 of
43 (23%) patients in group A and 9 of 44 (20%) patients in group B had 1 or more
recurrent thromboembolic events (not statistically significant). A significant difference
was demonstrated only in patients with cancer; LTA was favored in reducing recurrent
DVT and PTS. Two other patients in group A had late significant complications sec-
ondary to warfarin (hemorrhage in 1 and coumadin necrosis in the other), with no com-
plications in group B. The mean number of days of hospitalization were fewer for
patients in group B (5 versus 8 days), which is mainly due to earlier initiation of war-
farin therapy for group B.
Conclusion: In this study of our local population, we observed that short-term antico-
agulation therapy was as effective as LTA therapy and less costly for use in most patients.
It may also carry less risk of long-term warfarin complications, such as bleeding or skin
necrosis. (J Vasc Surg 1998;28:630-7.)
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anticoagulation (3 to 12 months).2-6 These studies
used varying modalities not only for diagnosis but
also for follow-up examinations. A diagnosis of DVT
was made in these studies by duplex ultrasound,
venography, or iodine-125-labeled fibrinogen scan-
ning or solely clinical examination.
The real problem concerns follow-up examina-
tions of these patients. Recurrent DVT is a difficult
clinical diagnosis to ascertain due to the incidence of
post-thrombotic syndrome in this population.7 A
decision must be made as to which diagnostic test
will be used to follow these patients and whether the
results of this test will alter the treatment course.
A study evaluating short- versus long-term anti-
coagulant therapy must involve close follow-up of
patients with serial duplex ultrasound examinations.
Duplex ultrasound will provide both anatomic and
physiological data for analysis and has become the
standard modality for venous imaging and DVT
diagnosis.8 This is the ideal method for diagnosis
and follow-up examinations for patients with DVT,
not only because of its noninvasive nature but also
because of its ability to provide both anatomic and
physiological information.
Clearly, not all patients require 3 to 6 months of
anticoagulant therapy after the first episode of DVT.
How can it be determined which patients, if any,
experience a significant change in the venous anatomy
or flow during this time that would justify the bene-
fits of anticoagulation therapy? Does anticoagulation
therapy alter the natural history of abnormalities seen
on duplex ultrasonography? Do the benefits of long-
term anticoagulation therapy outweigh the risks of
adverse reactions? In this study, we compare the
results of short-term versus conventional long-term
anticoagulation therapy in patients with DVT of the
lower extremity.
PATIENTS AND METHODS
This was a prospective controlled study of 105
patients who were hospitalized (January 1987
through December 1994) for symptomatic unilater-
al DVT of the lower extremity. These were consecu-
tive in-patients who were clinically suspected of hav-
ing DVT, and they were referred by their physicians
to the vascular laboratory at Charleston Area
Medical Center/Robert C. Byrd Health Sciences
Center of West Virginia University (Charleston,
WV). Patients with a past history of DVT or pul-
monary embolism, isolated calf vein thrombosis,
hypercoagulable states (including protein C, protein
S, and antithrombin III deficiencies or lupus antico-
agulation antibodies), and DVT during pregnancy
were excluded from this study. Before anticoagula-
tion was initiated, blood samples were obtained
from young patients (younger than 50 years) and
those with a family history of venous thrombosis for
measurement for protein C, protein S, antithrombin
III, and lupus anticoagulant antibodies. Factor V
Leiden was not tested routinely during that period
of our study.
Baseline assessments of DVT symptoms, risk fac-
tors, and demographic data were recorded.
Diagnosis was made using duplex ultrasound in all
patients, and some patients also had ascending
venography of the lower extremity. This included 24
patients who underwent both venous imaging and
venography for correlation regarding an earlier
study.9 Later, 2 additional patients underwent both
tests because the venous image was not conclusive.
Patients were sequentially assigned to 1 of the
following hospital treatment protocols. Patients in
group A received conventional long-term anticoag-
ulation therapy, which included an initial course of
full-dose intravenous standard heparin (maintaining
the activated partial thromboplastin time at 1.5- to
2-fold of control), followed by warfarin on days 3 to
5 of treatment (with an INR of 2 to 3 or a pro-
thrombin time of 1.5- to 2-fold of the control) and
was continued for 3 months for patients without
pulmonary embolism. Patients in group B received
short-term therapy, which included the same
heparin therapy followed by warfarin on day 2 or 3
of treatment and was continued for only 6 weeks.
The rationale behind initiation of warfarin on
days 3 to 5 of treatment for group A patients was
based on the assumption by many physicians in the
past, including some of the internists who referred
these patients, that therapeutic anticoagulation with
heparin should be obtained before warfarin adminis-
tration and continued for 3 to 5 days until low
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Table I. Patients Enrolled and Analyzed in the
Study
Group A Group B 
Number of patients enrolled 54* 51*
Excluded from primary analyses for: 11 7
Lost to follow-up† 4 2
Early complications 4 3
Deaths 3 2
Included in primary analyses 43 44
Included in intention-to-treat 54 51
analysis
*One patient was mistakenly assigned to group A instead of
group B.
†No follow-up available after hospital discharge.
steady state levels of coagulation factors are
achieved.10,11 This is based on the fact that concen-
trations of protein C and S are also reduced by war-
farin. Protein C half-life is only 4 to 6 hours; thus, lev-
els are reduced early in warfarin therapy, creating the
potential for a transient procoagulation state, especial-
ly in patients with preexisting protein C deficiencies.
Recently, however, many researchers are recommend-
ing that warfarin therapy be administered almost on
the same day as initiation of heparin therapy. Because
of this, we thought that it was appropriate to start
warfarin therapy in group B patients within 24 hours.
All patients in group B had warfarin treatment initiat-
ed on the second day of hospitalization, except for the
3 patients who had early major complications.
When a stable INR within the target range had
been achieved, the test was repeated weekly for the
first 6 weeks for the short-term anticoagulation ther-
apy group and then every 2 to 3 weeks for the remain-
ing period in the long-term anticoagulation therapy
group. Effective anticoagulation therapy in each
patient was defined as an INR of more than 2 in at
least 67% of the tests for that patient.12 This was
achieved in 35 of 43 (81%) in group A and 37 of 44
(84%) in group B patients (ie, similar in both groups). 
All patients were followed by duplex ultrasound
scan at 6 weeks, 3 and 6 months, and every 6 months
thereafter. Patients were also examined for the pres-
ence of edema, brawny induration, skin pigmentation
in the gaiter area of the lower leg, or ulceration. All
patients were instructed to wear graduated compres-
sion stockings (Sigvaris or Jobst) for at least 2 years. 
The data were analyzed, and comparisons
between groups were made by means of Fisher’s
exact test, c 2 test, and 95% confidence interval.
Duplex scanning. Duplex imaging studies were
performed with an Ultramark 8 or 9 HDI color
scanner (Advanced Technology Laboratory, Bothell,
Wash) using a 5- or 7.5-MHz linear transducer, and
pulsed Doppler signals were obtained using a 5-
MHz probe. Veins examined were the iliac, common
femoral, superficial femoral, popliteal, and proximal
tibial calf veins. All tests were interpreted blindly,
without the knowledge of the treatment protocol.
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Table II. Effect of Short-Term (Group B) versus Long-Term (Group A) Anticoagulation on the Incidence
of Postphlebitic Syndrome
Risk factor PPS No PPS Total With PPS P
Stasis
Group A 2 2 4 50%
Group B 2 3 5 40%
Total 4 5 9 44% Fisher’s exact P = .64
Trauma
Group A 3 4 7 43%
Group B 3 5 8 38%
Total 6 9 15 40% Fisher’s exact P = .62
Cancer
Group A 3 7 10 30%
Group B 7 1 8 88%
Total 10 8 18 56% Fisher’s exact P = .02
Postoperative
Group A 4 6 10 40%
Group B 3 8 11 27%
Total 7 14 21 33% Fisher’s exact P = .44
Medical
Group A 3 3 6 50%
Group B 3 4 7 43%
Total 6 7 13 46% Fisher’s exact P = .62
Unknown
Group A 3 3 6 50%
Group B 2 3 5 40%
Total 5 6 11 45% Fisher’s exact P = .61
All patients 95% Confidence interval
Group A 18 25 43 42% 27.1 to 56.6
Group B 20 24 44 45% 30.7 to 60.2
Total 38 49 87 44% 
PPS, Postphlebitic syndrome.
For all patients, Fisher’s exact P = .45, c 2 = 0.90.
Reflux assessment using a 5-MHz pulsed
Doppler probe placed centerstream at a 60-degree
angle to the direction of the flow also was done.
Assessment of reflux in the proximal veins (common
femoral and proximal superficial veins) was made by
performing the Valsalva maneuver, and reflux assess-
ment for the mid and distal superficial femoral veins
and the proximal and distal popliteal veins was made
with compression over proximal muscle groups.
Reversed flow lasting longer than 2 seconds was
required for the diagnosis of reflux.7,13 Imaging of
the anterior tibial veins and the peroneal veins was
not routinely done, particularly in the first several
years of this study.
Our venous duplex interpretation criteria for
acute DVT were reported previously.9 The follow-
ing criteria were used to consider the resolution of
the DVT process: a return of the phasic Doppler
signal with respiration and augmentation maneu-
vers, disappearance of the intraluminal echoes, and
the ability to fully compress the vein in the trans-
verse position by gentle pressure of the transducer.
The following criteria were also used to character-
ize chronic phlebitic changes or nonresolution of
DVT during follow-up: abnormal thickening or
increased echogenicity of the vein wall, abnormal
valve motion with the presence of reflux, or an
occluded vein.
Recurrence of the DVT process was diagnosed
when the previously mentioned criteria for DVT
reappeared in a vein segment that had previously
been considered normal or resolved.
Therefore, the outcome of DVT according to
duplex scanning follow-up was divided into com-
plete resolution (normal), chronic phlebitic changes,
or recurrence of DVT.
Definitions. The term “post-thrombotic syn-
drome,” or changes, was used in the presence of
chronic postphlebitic changes on the duplex ultra-
sound as described previously, with or without clin-
ical signs of postphlebitic syndrome (ie, leg swelling,
hyperpigmentation, and/or ulceration). Significant
hemorrhage was defined as major when transfusion
treatment was needed, when hemoglobin concentra-
tion fell by 2 g/dL, or when it was retroperitoneal
or cerebral. All cases of pulmonary embolism were
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 4 AbuRahma, Stickler, and Robinson 633
Table III. Effect of Short-Term (Group B) versus Long-Term (Group A) Anticoagulation on the
Incidence of Recurrent DVT
Risk factor Recurrent DVT No recurrent DVT Total Total with recurrent DVT P
Stasis
Group A 1 3 4 25%
Group B 1 4 5 20%
Total 2 7 9 22% Fisher’s exact P = .72
Trauma
Group A 1 6 7 14%
Group B 0 8 8 0%
Total 1 14 15 7% Fisher’s exact P = .47
Cancer
Group A 2 8 10 20%
Group B 6 2 8 75%
Total 8 10 18 44% Fisher’s exact P = .03
Postoperative
Group A 2 8 10 20%
Group B 0 11 11 0%
Total 2 19 21 10% Fisher’s exact P = .21
Medical
Group A 2 4 6 33%
Group B 1 6 7 14%
Total 3 10 13 23% Fisher’s exact P = .44
Unknown
Group A 2 4 6 33%
Group B 1 4 5 20%
Total 3 8 11 27% Fisher’s exact P = .58
All patients 95% Confidence interval
Group A 10 33 43 23% 10.63 to 35.88
Group B 9 35 44 20% 8.54 to 32.37
Total 19 68 87 22% 
For all patients, Fisher’s exact P = .48, c 2 = .95.
documented by ventilation-perfusion lung scans and
pulmonary angiograms.
Ventilation-perfusion lung scans were done in all
patients with clinical suspicion of pulmonary
embolism: 4 in group A (3 of these at the initial hos-
pitalization and 1 at late follow-up [25 months]).
Two of the 4 had a high probability ventilation-per-
fusion lung scan, and both were confirmed by pul-
monary angiography. The other patient had a low
probability ventilation-perfusion lung scan with a
negative pulmonary angiogram, and the last patient
had a normal scan. Three patients in group B had
ventilation-perfusion lung scans: 2 during hospital-
ization; 1 patient had a high probability scan that
was confirmed by angiography, and 1 had a low
probability scan with a negative angiogram. The
third patient had a low probability scan and negative
angiogram at late follow-up (18 months).
To simplify the analysis of the results, risk factors
were stratified into the following: malignancy, trau-
ma, postoperative DVT (excluding trauma), pro-
longed stasis (cerebrovascular accident or others),
medical reasons (including patients with multiple-
system failure, patients in medical intensive or car-
diac care unit), and unknown (if there were no iden-
tifiable risk factors).
RESULTS
All patients who met the study entry criteria were
enrolled sequentially into either treatment group A
(standard anticoagulation regimen; 54 patients) or
group B (shortened regimen; 51 patients), except
for 1 patient who was mistakenly assigned to stan-
dard therapy (group A) instead of group B. Eleven
patients in group A and 7 patients in group B were
excluded from the primary analyses (Table I). All
105 patients were examined in a secondary inten-
tion-to-treat analysis, based on the data available
through their last follow-up.
There were 4 immediate major complications in
group A (4 of 54 [7%], 2 with pulmonary embolism
and 2 with significant bleeding with an INR of 3.2
in 1 and 6 in the other) and 3 in group B (3 of 51
[6%], 1 with pulmonary embolism and 2 with bleed-
ing with an INR of 2.5 in 1 and 5.6 in the other).
All of these 7 patients had inferior vena cava filter
insertion. There were 5 late deaths: 3 in group A (2
myocardial infarctions and 1 malignancy) and 2 in
group B (secondary to myocardial infarction).
Risk factors, location of venous thrombosis, and
the mean age (52 years in group A and 54 years in
group B) of the groups were comparable. Follow-up
ranged from 26 to 95 months, with a mean of 59
months. In long-term follow-up, 18 of 43 (42%)
patients in group A and 20 of 44 (46%) patients in
group B had post-thrombotic sequelae. Only 3
patients in group A and 4 patients in group B had
venous reflux without clinical postphlebitic changes.
An analysis of the data with or without this group
was not statistically significant. The remaining 15
patients in group A included 4 stage I patients (mild
to moderate lower limb edema and mild skin
changes), 8 stage II patients (marked trophic changes
with hyperpigmentation, subcutaneous fibrosis,
eczematoid changes, and edema), and 3 stage III
patients (venous ulceration). The 16 patients in
group B included 5 patients with stage I, 7 patients
with stage II, and 4 patients with stage III. Similarly,
10 of 43 (23%) patients in group A and 9 of 44 (20%)
patients in group B had 1 or more documented
recurrent venous thromboembolic events (not statis-
tically significant; Tables II and III).
The locations of these recurrent thromboem-
bolic events were similar in both groups. Nine of 10
in group A and all 9 events in group B were locat-
ed in the femoropopliteal veins. One patient in
group A was localized to below-the-knee popliteal
veins and proximal tibial veins. No documented
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Table IV. Intention-to-Treat Analysis of All Patients
Number with complications Percent with complications 95% Confidence interval
All complications*
Group A 34/54 63% 50.1 to 75.8
Group B 34/51 68% 53.7 to 79.6
Postphlebitic syndrome
Group A 20/54 37% 24.2 to 49.9
Group B 22/51 43% 29.5 to 56.7
DVT
Group A 10/54 19% 8.2 to 28.9
Group B 9/51 18% 7.2 to 28.1
*Including postphlebitic syndrome, DVT, pulmonary emboli (n = 3) and significant bleeding (n = 4).
cases of pulmonary embolism were noted during
the follow-up period.
Two patients in group A had late significant
complications secondary to warfarin (hemorrhage in
1 with an INR of 5.2 and coumadin necrosis in the
other), but none occurred in group B. 
As noted in Tables II and III, when patients were
classified according to risk factors, there were no sta-
tistically significant differences between groups A and
B in the incidence of recurrent DVT or postphlebitic
syndrome in patients with stasis, trauma, or postop-
erative DVT; in medical patients; or in patients with
unknown causes for DVT. However, the incidence of
recurrent DVT or postphlebitic syndrome was statis-
tically significantly higher in patients with malignan-
cy (75% for group B versus 20% for group A and 88%
for group B versus 30% for group A, respectively).
An intention-to-treat analysis was performed to
assess whether the excluded patients (as seen in Table
I) had any impact on the conclusions drawn from the
study. All early and late complications were included
in the analysis, as were the last data available on the 5
patients excluded because of death (Table IV). The
patient who was mistakenly assigned to group A
instead of group B was evaluated according to the
treatment he actually received (standard therapy). As
with the primary analysis, there was substantial over-
lap of the 95% confidence intervals, suggesting mini-
mal differences in the rates of complications. 
The mean days of hospitalization were shorter
for group B patients (5 days versus 8 days for group
A), which is mainly due to the earlier initiation of
warfarin therapy in group B.
DISCUSSION
This study has shown that the current treatment
regimen for acute DVT should be questioned. The
current practice has been to anticoagulate patients
for a minimum of 3 months. This study has shown
that this protocol may not be necessary in some
patients and may also carry some increasing risk of
warfarin complications. 
The modest size of this study suggests that the
power to detect a significance between the two
treatment groups is limited. Power calculations esti-
mate that a study of approximately 60 patients per
treatment group would be needed to have a 50%
likelihood of detecting a 25% worse rate of overall
complications in the short-term anticoagulation
group compared with the standard anticoagulation
group (with an a value of P = .05). A study of simi-
lar size would have a 50% likelihood of detecting a
50% higher rate of postphlebitic syndrome in the
short-term group compared to the standard therapy
(a = .05). However, the extremely small differences
between the two treatment groups in rates of post-
phlebitic syndrome, DVT, and overall complications
substantiates the conclusion that a clinically mean-
ingful difference in risk of these complications is
unlikely. Furthermore, unlike other larger stud-
ies,2,14 this study has the advantage of evaluating
patients in a single center, who were evaluated by a
limited number of investigators. In addition, almost
all patients (99 of 105 [94%]) had an objective eval-
uation for recurrent DVT and postphlebitic syn-
drome using venous duplex imaging. Thus, what the
study lacks in power is balanced by the consistency
in patient evaluation and data collection.
Duplex ultrasonography has provided a conve-
nient and noninvasive means to serially examine
patients with acute DVT and thus to accurately doc-
ument the natural history of this condition.
The Research Committee of the British Thoracic
Society2 compared short-term (4 weeks) with long-
term (3 month) therapy and found a higher recur-
rence rate with the short-term therapy (15% versus
8%). One of the problems with this study, however,
was that the objective tests used to confirm suspect-
ed failures were done on only 38% of the patients in
the 4-week group and 48% of those in the 3-month
group. When only those with confirmed failures
were compared, the difference was not statistically
significant. These reported failure rates were signifi-
cantly lower than the rates of other studies, which
reported an approximate failure rate of 30%.11,13,15
These rates were based on failure of clot resolution
or clot propagation. The failure rate in our study was
approximately 22% overall with an objective confir-
mation of all failures. We could not demonstrate a
statistically significant difference in the failure rates
between the 6-week and 3-month groups when all
patients were combined, regardless of risk factors. It
should be noted that we may have underestimated
the incidence of recurrent DVT because we used
duplex imaging to examine the proximal major veins
(iliac, femoropopliteal) and the proximal tibial veins
only. Duplex ultrasound scan has also decreased sen-
sitivity in calf vein thrombosis in an asymptomatic
surveillance protocol. However, the same principle
was applied for both groups.
Levine et al4 used impedance plethysmography in
their study to determine whether patients should con-
tinue anticoagulation therapy after 4 weeks, but
because of post-thrombotic syndrome, these results
failed to differentiate between reflux and obstruc-
tion.16-18 This study concluded that patients with
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abnormal impedance plethysmography studies at 4
weeks should continue warfarin therapy for 3 months.
Again, duplex ultrasonography can differentiate
abnormalities secondary to occlusion versus reflux.
Schulman et al14 compared patients who were ran-
domized into 6 weeks versus 6 months of anticoagula-
tion therapy. They found that recurrence rates were
higher in the 6-week group (20%) than in the 6-
month group (11%). There were 2 problems identified
in this study; first, their exclusion criteria for enroll-
ment was too strict, particularly the exclusion of
patients with malignancy and prolonged immobility,
and, second, they did not objectively examine all
patients at follow-up. The patients who received objec-
tive study were only those patients with symptoms.
Complications secondary to warfarin therapy are
another important consideration in these patients.
In our study, 1 patient developed a significant bleed-
ing complication and 1 developed skin necrosis. This
does not include minor hemorrhages. This correlat-
ed to an approximate 4% complication rate, which
was similar to that found in the Research Committee
study (3%).2
The question remains as to whether patients can
be stratified into those who will require long-term
versus short-term therapy and as to what defines
long-term and short-term therapy. The Research
Committee of the British Thoracic Society2 consid-
ered medical versus postoperative patients and con-
cluded that the incidence of recurrence and nonres-
olution was significantly higher in the medical group
of patients who were given short-term anticoagula-
tion. We subclassified the patient population even
further, breaking down the medical group into med-
ical, stasis, and cancer, as stated earlier. We failed to
demonstrate a statistically significant difference in
the medical and stasis versus surgical groups with
regard to recurrence of DVT and post-thrombotic
syndrome in short- versus long-term anticoagula-
tion. However, there was a difference in recurrence
in the subcategory of cancer patients. A statistically
significant difference was demonstrated favoring
long-term anticoagulation for the development of
post-thrombotic syndrome and for recurrence of
DVT. However, the numbers in this subset of
patients were too small for reliable conclusions. One
interesting finding in the subclassification was that
the trauma and postoperative groups had a similar
low rate of DVT recurrence compared with the
other groups; however, the incidence of post-throm-
botic syndrome was similar.
Short-term therapy has principally been defined
by the 4-week to 6-week interval because the major-
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ity of clot lysis and recanalization occurs in the first
1 to 3 weeks after acute DVT. This has been corre-
lated to the increased activity of tissue plasminogen
activator and the decreased activity of plasmin acti-
vator inhibitor-1.19 This may explain why clot per-
sistence or propagation occurs despite adequate
anticoagulation.
Although it was not the intention of this study,
treatment of DVT with low-molecular-weight
heparins have been advocated in several studies in
the past few years. Recently introduced low-molecu-
lar-weight heparin preparations can be administered
subcutaneously, once or twice daily, without labora-
tory monitoring. Lensing et al20 quantitatively
assessed the relative efficacy and safety of low-mole-
cular-weight heparin versus standard heparin for the
initial treatment of DVT. Reports of randomized tri-
als that were written in English between 1984 and
1994 were identified through a Medline search, and
a complementary extensive manual search was con-
ducted. They assessed the incidence of symptomatic
recurrent venous thromboembolic disease, the inci-
dence of clinically important bleeding, and mortali-
ty. Ten of 19 identified trials satisfied their predeter-
mined criteria. The relative risk reductions for symp-
tomatic thromboembolic complications (53% [95%
confidence interval, 18% to 73%]), clinically impor-
tant bleeding (68% [95% confidence interval, 31% to
85%]), and mortality (47% [95% confidence interval,
10% to 69%]) were all statistically significantly in
favor of the use of low-molecular-weight heparin.
The researchers concluded that low-molecular-
weight heparins administered subcutaneously in
fixed doses adjusted for body weight and without
laboratory monitoring are more effective and safer
than adjusted-dose standard heparin. They also
believed that definitive randomized controlled trials
for other low-molecular-weight heparins are
required. Recently, Koopman et al21 randomized
assigned patients to receive adjusted-dose intra-
venous standard heparin administered in the hospi-
tal (198 patients) or fixed-dose subcutaneous low-
molecular-weight heparin administered at home,
when feasible (202 patients). They compared the
treatments with respect to recurrent venous throm-
boembolism, major bleeding, quality of life, and
costs. Seventeen of the 198 patients who received
standard heparin (8.6%) and 14 of the 202 patients
who received low-molecular-weight heparin (6.9%)
had recurrent thromboembolism (difference, 1.7
percentage points; 95% confidence interval, –3.6 to
6.9). Major bleeding occurred in 4 patients assigned
to standard heparin (2%) and 1 patient assigned to
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low-molecular-weight heparin (0.5% difference, 1.5
percentage points; 95% confidence interval, –0.7 to
2.7). Quality of life improved in both groups. They
also believed that physical activity and social func-
tioning were better in the patients assigned to low-
molecular-weight heparin. Among the patients in
that group, 36% were never admitted to the hospi-
tal, and 40% were discharged early. This treatment
was associated with a mean reduction in hospital
days of 67%, ranging from 29% to 86% in the various
study centers. They concluded that in patients with
proximal vein thrombosis, treatment with low-mol-
ecular-weight heparin at home is feasible, effective,
and safe.
Although the results of the use of low-molecular-
weight heparin are promising, its implication in our
study and similar studies is still uncertain. Therefore,
a study comparing the efficacy of short-term versus
long-term anticoagulation therapy using low-molec-
ular-weight heparin is warranted. 
In conclusion, our study demonstrates that out-
comes of short- versus long-term treatment of acute
DVT without pulmonary embolism are similar,
except in cancer patients. It also shows that compli-
cations from long-term anticoagulation exist, and
because benefit has not been demonstrated in many
patients, short-term therapy for acute DVT should
be considered in certain patients. The cost aspect
should also be considered. Patients on short-term
therapy will save not only money on drugs but also
on laboratory testing. However, because the num-
ber of patients in this series is not large, the conclu-
sions must be confirmed by other studies. 
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